筛选
科学数据
统计数据
共检索到626条 ,权限内显示50条;
Data from: A Curated Cancer Clinical Outcomes Data Base (C3OD) for accelerating patient recruitment in cancer clinical trials
- 负责人：
- DOI：
- doi:10.5061/dryad.1mq2ts3
- 摘要：
- Data used to determine patient eligibility for cancer clinical trials often come from disparate sources that are typically maintained
Data from: Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS
- 负责人：
- DOI：
- doi:10.5061/dryad.2h2g698
- 摘要：
- entre dataset. Methods. MRI and clinical evaluations were acquired from 179 controls and 435 patients (35 clinically isolated syndromes [CIS], 259 relapsing
Data from: Evaluating adherence to the International Committee of Medical Journal Editors’ policy of mandatory, timely clinical trial registration
- 负责人：
- DOI：
- doi:10.5061/dryad.1q030
- 摘要：
- and Methods: Observational study using computerized analysis of publicly available MEDLINE article data and clinical trial registry data. We analyzed
Data from: Distinct epileptiform abnormalities are associated with clinical seizures in Alzheimer’s disease
- 负责人：
- DOI：
- doi:10.5061/dryad.8gtht76kc
- 摘要：
- al biomarkers relate to the clinical expression of seizures in AD. Methods: In this cross-sectional study, we performed 24-hour ambulatory scalp EEGs on 43
Data from: Quality expectations and tolerance limits of trial master files (TMF) - Developing a risk-based approach for quality assessments of TMFs
- 负责人：
- DOI：
- doi:10.5061/dryad.t2f61
- 摘要：
- s the TMF need to have so that a clinical trial can be adequately reconstructed from documented data and procedures? Clinical trial sponsors face signific
Data from: Assessment of disease progression in dysferlinopathy – a one year cohort study
- 负责人：
- DOI：
- doi:10.5061/dryad.tp08m60
- 摘要：
- patients with dysferlinopathy were recruited to the Jain Foundation’s International Clinical Outcome Study for Dysferlinopathy. Baseline, 6 months and 1 yea
Data from: Terminated trials in the ClinicalTrials.gov results database: evaluation of availability of primary outcome data and r
- 负责人：
- DOI：
- doi:10.5061/dryad.v5403
- 摘要：
- Background: Clinical trials that end prematurely (or “terminate”) raise financial, ethical, and scientific concerns. The extent to which the result
Data from: Total A?42/A?40 ratio in plasma predict amyloid-PET status, independent of clinical AD diagnosis
- 负责人：
- DOI：
- doi:10.5061/dryad.f300d56
- 摘要：
- antially reducing the screening rate of failure (SRF) for clinical trials targeting pre-clinical or prodromal disease. Classification of evidence: This study prov
Data from: Automatic recognition of self-acknowledged limitations in clinical research literature
- 负责人：
- DOI：
- doi:10.5061/dryad.06ds7
- 摘要：
- Objective: To automatically recognize self-acknowledged limitations in clinical research publications to support efforts in improving rese
Data from: Genetic mapping of novel loci affecting canine blood phenotypes
- 负责人：
- DOI：
- doi:10.5061/dryad.30c8p
- 摘要：
- for disease studies. For many of these dogs, additional clinical phenotypes are available, such as hematological and clinical chemistry results collected duri
